Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 4:46 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 2,002 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Discrete Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Cerebrovascular Response to Acute Exercise

NCT03722953
View directory record Official record
Conditions
Healthy, Physical Activity
Interventions
Control, Aerobic Exercise
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
20 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Nov 2, 2026, 4:46 PM EST
Not listed Phase 2 Interventional

Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

NCT00675870
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
NRX 195183 Soft Gelatin Capsule
Drug
Lead sponsor
NuRx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 12, 2008 · Synced Nov 2, 2026, 4:46 PM EST
Completed Phase 1 Interventional

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

NCT02993237
View directory record Official record
Conditions
HIV-1
Interventions
DRV/COBI FDC placebo tablet, D/C/F/TAF FDC placebo tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Nov 2, 2026, 4:46 PM EST
Terminated Phase 2 Interventional Results available

Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment

NCT02317783
View directory record Official record
Conditions
Breast Cancer
Interventions
[18F]Flutemetamol, [18F]fluoro-2-deoxy-D-glucose (FDG), Functional Magnetic Resonance Imaging (fMRI)
Drug · Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Nov 2, 2026, 4:46 PM EST
Completed Not applicable Interventional Results available

Strategies to Enhance New CGM Use in Early Childhood (SENCE)

NCT02912728
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM + Family Behavioral Intervention, Standard CGM
Behavioral · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
2 Years to 7 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 2, 2026, 4:46 PM EST
Completed Phase 3 Interventional Results available

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

NCT00699751
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer, Bone Metastases
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Best standard of care (BSoC)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
7
States / cities
Los Angeles, California • Roseville, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Nov 2, 2026, 4:46 PM EST
Withdrawn Not applicable Interventional

Comparison of Three Approaches of Electrode Placement to Detect Changes in Motor Evoked Potentials During Spine Surgery

NCT05098431
View directory record Official record
Conditions
Intervertebral Disc Degeneration, Intervertebral Disc Displacement, Spinal Stenosis, Spinal Curvatures, Spondylitis, Spondylosis
Interventions
Quadriceps and Rectus Femoris MEP Recording
Other
Lead sponsor
Allina Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Nov 2, 2026, 4:46 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Theta Connectivity in Working Memory

NCT05204381
View directory record Official record
Conditions
Executive Function
Interventions
Theta-frequency near-zero phase lag stimulation, Theta-frequency anti-synchrony stimulation, Arrhythmic near-zero phase lag stimulation, Arrhythmic independent stimulation, Alpha-frequency near-zero phase lag stimulation, Alpha-frequency anti-synchrony stimulation
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Nov 2, 2026, 4:46 PM EST
Completed Not applicable Interventional Results available

Diagnosing Intensive Care Unit (ICU) Acquired Weakness

NCT04166630
View directory record Official record
Conditions
ICU Acquired Weakness
Interventions
Clinical Electrical Stimulator
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Nov 2, 2026, 4:46 PM EST
Completed Phase 3 Interventional Results available

Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep

NCT01073930
View directory record Official record
Conditions
Bowel Preparation
Interventions
PicoPrep, HalfLytely, bisacodyl
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Huntsville, Alabama • Sherwood, Arkansas • Bristol, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Nov 2, 2026, 4:46 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

PRINT Trial (Platelet Rich Injection vs Needle Tenotomy)

NCT03504111
View directory record Official record
Conditions
Lateral Epicondylitis, Tendinosis, Elbow, Tennis, Elbows Tendonitis
Interventions
Percutaneous Needle Tenotomy, PRP
Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Nov 2, 2026, 4:46 PM EST
Completed Not applicable Interventional Results available

Prospective Study for Symptomatic Relief of ET With Cala Therapy

NCT03597100
View directory record Official record
Conditions
Essential Tremor
Interventions
Cala TWO
Device
Lead sponsor
Cala Health, Inc.
Industry
Eligibility
22 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
32
States / cities
Phoenix, Arizona • Los Angeles, California • Mountain View, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Nov 2, 2026, 4:46 PM EST
Completed Phase 2 Interventional Results available

Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor

NCT00582933
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Allogeneic Marrow Transplant
Interventions
BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 54 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Nov 2, 2026, 4:46 PM EST
Terminated Phase 2 Interventional Accepts healthy volunteers

Protein Supplementation in Dialysis Patients

NCT00367198
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Pro-Stat
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Nov 2, 2026, 4:46 PM EST
Not listed Not applicable Interventional

Field Test of Motivity.Net Software for Data Collection During Behavioral Interventions

NCT03919721
View directory record Official record
Conditions
Autistic Disorder
Interventions
Applied Behavioral Analysis
Behavioral
Lead sponsor
Experiad LLC
Industry
Eligibility
2 Years to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Nov 2, 2026, 4:46 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Experiment 2: One Target in Many Situations

NCT06934148
View directory record Official record
Conditions
Vision, Healthy, Attention
Interventions
Blocked Trials, Mixed trials
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 2, 2026, 4:46 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Cardiovascular Function and Response to Stimulation Within the First Year After Spinal Cord Injury

NCT06841198
View directory record Official record
Conditions
Spinal Cord Injuries (SCI), Orthostatic Hypotension, Dysautonomic, Cardiovascular, Transcutaneous Spinal Stimulation
Interventions
spinal cord transcutaneous stimulation, Ice testing
Device · Procedure
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 2, 2026, 4:46 PM EST
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

NCT04786106
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH), Penile Plication Surgery, Incision and Grafting (I&G) Surgery, RestoreX Penile Traction Device
Drug · Procedure · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 2, 2026, 4:46 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03178552
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
12
States / cities
Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 2, 2026, 4:46 PM EST
Completed Not applicable Interventional Results available

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

NCT00624585
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Dasatinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Nov 2, 2026, 4:46 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Ethnicity on Changes in VO2max and Cardiac Output in Response to Short-Term High Intensity Interval Training

NCT04449016
View directory record Official record
Conditions
Improved VO2max and Cardiac Output in Response to Training
Interventions
High intensity interval training
Other
Lead sponsor
California State University, San Marcos
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Marcos, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Nov 2, 2026, 4:46 PM EST
Terminated Phase 3 Interventional Results available

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

NCT01955733
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695500
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 82 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Nov 2, 2026, 4:46 PM EST
Recruiting Phase 1 Interventional

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

NCT06452316
View directory record Official record
Conditions
Limbal Stem Cell Deficiency
Interventions
CSB-001 Ophthalmic Solution 0.1%
Biological
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Loma Linda, California • Carmel, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 2, 2026, 4:46 PM EST
Terminated Phase 1 Interventional

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT05737706
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
Interventions
MRTX1133
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Nov 2, 2026, 4:46 PM EST